title: The use of nerve growth factor as a reverse transforming agent for the treatment of neurogenic tumors: in vivo results.
abstract: The rationale behind the evaluation of natural differentiating agents, such as nerve growth factor (NGF), for reverse transforming potential is based on the theory that such compounds may represent a nontoxic means of controlling tumor growth. Previous in vitro experiments have shown that NGF is capable of retarding growth and of inducing persistent differentiation of neurogenic tumor cell lines. In vivo, NGF is capable of causing a persistent reduction in the number of ethylnitrosourea-induced neurinomas and of increasing survival time following intracerebral implantation of F98 anaplastic glioma cells. In this study, anaplastic glioma and neurinoma implants were treated with NGF to evaluate the reverse transforming potential of NGF in vivo. Results indicate that NGF is capable of causing a significant decrease in the growth rate of subcutaneous T9 (anaplastic glioma) and clone 16 (anaplastic neurinoma) implants. Significantly, NGF treatment was accompanied by adverse effects that were minimal and transient. Continued tumor growth (although greatly retarded) following NGF treatment is an aspect that requires further investigation. However, the results of this study suggest that NGF may prove useful, alone or in combination with other types of therapy, for the treatment of tumors of neurogenic origin.
authors.affiliation: Department of Pathology, Michigan State University, East Lansing 48824.
authors.forename: M J
authors.initials: MJ
authors.lastname: Yaeger
authors.forename: A
authors.initials: A
authors.lastname: Koestner
authors.forename: K
authors.initials: K
authors.lastname: Marushige
authors.forename: Y
authors.initials: Y
authors.lastname: Marushige
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D002999:Clone Cells; D004797:Enzyme-Linked Immunosorbent Assay; D005910:Glioma / Q000188:drug therapy; D007150:Immunohistochemistry; D009368:Neoplasm Transplantation; D009414:Nerve Growth Factors / Q000627:therapeutic use*; D009423:Nervous System Neoplasms / Q000188:drug therapy*; D010641:Phenotype; D051381:Rats; D011916:Rats, Inbred F344; D011956:Receptors, Cell Surface / Q000187:drug effects; D017475:Receptors, Nerve Growth Factor
chemical_list: D000970:Antineoplastic Agents; D009414:Nerve Growth Factors; D011956:Receptors, Cell Surface; D017475:Receptors, Nerve Growth Factor